HRS 2018 Roundup: Researchers highlight the latest in cardiac ablation tech

There are lots of new opportunities in ablation, evidenced by the research touted at this year’s annual meeting of the Heart Rhythm Society in Boston. Scientists presented data from trials evaluating cardiac ablation via pulsed electric fields, intramural needle ablation and more. Editors at MassDevice.com asked leading cardiac electrophysiologist Dr. Vivek Reddy, will there someday be one catheter to rule them all? “As in most things, there will always be several,” he explained. Here’s a look at some of the ablation technology presented at this year’s meeting. Intramural needle ablation for stubborn ventricular arrhythmia –  Using an irrigated needle ablation catheter from Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster, researchers evaluated safety and 6-month efficacy outcomes for patients with refractory ventricular arrhythmia. Currently-available ablation technologies are not designed to work in the ventricular space, Reddy said. This trial aimed to evaluate Biosense’s device in 31 patients who have not responded to standard catheter ablation or antiarrhythmic drugs. The researchers selected target sites based on endocardial mapping and then deployed the 27-gauge needle up to 10mm into the myocardium for recording and pace-mapping. Then, the scientists irrigated with contrast/saline for RF ablation, with current titrated to a maximum needle temperature of 60oC, they said. “All of the patients had failed using ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials Wall Street Beat BioSense Webster Inc. Boston Scientific johnsonandjohnson Medtronic Source Type: news